Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 4 1

Status

Completed 34Recruiting 20Unknown 18Terminated 5Withdrawn 4Not yet recruiting 3Active not recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Prolymphocytic, T-Cell 1

Interventions

Cisplatin 122Carboplatin 120Drug Therapy 104Bevacizumab 101Capecitabine 96Oxaliplatin 95Radiotherapy 92Gemcitabine 88Paclitaxel 87tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 66Magnetic Resonance Spectroscopy 63Fluorouracil 61sintilimab 58Injections 57anlotinib 51Docetaxel 51Surgical Procedures, Operative 48130-nm albumin-bound paclitaxel 48fludarabine 45Pemetrexed 43Standard of Care 42Biopsy 42venetoclax 41Irinotecan 41lenvatinib 40Leucovorin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Cladribine × Clear all
NCT07053020 2026-03-04

A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
58 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

NCT06763666 2025-01-08

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Nanfang Hospital, Southern Medical University

Phase 4 Not yet recruiting
172 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡